Signum U.S. Healthcare,  Inc.

Signum is in currently implementing multiple CyberKnife® sites in China in close collaboration with its joint venture partners.  Partners and investors frequently desire detailed information about the CyberKnife® and its capabilities.  The following description will provide some insight into this phenomenal technology.

CyberKnife® Description

CyberKnife® Description

Stereotactic radiosurgery is a non-invasive (non-surgical) treatment in which high doses of focused radiation beams are delivered from multiple locations outside the body to destroy a tumor or lesion within the body. This procedure does not remove the tumor or lesion. Instead, it destroys tumor cells or stops the growth of active tissue.  Traditional methods relied on a metal frame that was bolted to the skull in order to target the treatment. Because of the need for the metal frame, radiosurgery was not possible for tumors located outside of the head.  The procedure has been used for more than 30 years, and over 100,000 patients have been treated worldwide.

 

CyberKnife® is an entirely new approach to stereotactic radiosurgery because it can deliver targeted radiation to anywhere in the body, while minimizing exposure to surrounding normal tissue. It offers all of the advantages of radiosurgery, but without the need for a metal head frame. No invasive head frame or other rigid immobilization device is required.  However, there is a need for placement of very small markers (fiducials) via a needle for the treatment of targets outside of the head.  This may need to be done in the hospital before treatment.

 

With sub-millimeter accuracy, CyberKnife® can be used to treat tumors, cancers, vascular abnormalities and functional disorders. Best of all, it achieves surgical-like outcomes without surgery or incisions.

 

CyberKnife® is developed and manufactured by Accuray of Sunnydale, California.